NVCR
Novocure (NASDAQ: NVCR) reported strong Q2 2026 results with $184 million in net revenue, up 16%...
Article Summary
BUY- Novocure (NASDAQ: NVCR) reported strong Q2 2026 results with $184 million in net revenue, up 16% year-over-year, driven by 18% global active patient growth across indications, including 280 active patients on Optune Pax andCE Mark for locally advanced pancreatic cancer, Germany first market to launch in EU, and record net revenues and record active patients.
- NovoCure expects mid-to-high single-digit net revenue growth from Optune Gio, consistent quarterly gross margin in the mid-70s percent, and full-year guidance of mid- to high-single-digit revenue growth based on foreign exchange rates and Optune-driven growth in Tumor Treating Fields.
- Management highlighted the company's progress toward profitability as TTFields therapy launches in multiple markets, with the company continuing to advance its mission to extend survival in some of the most aggressive forms of cancer.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.5% | 25% | 35.0 ptsBelow Screener (8.5%) - Weak growth |
| EPS Growth Next 5Y ? | 23.5% | 25% | 70.0 ptsGood (23.5%) - Solid outlook |
| Target Price Upside ? | 23.2% | 20% | 70.0 ptsGood Upside (23.2%) - Target: $24.57 vs Current: $19.94 |
| Gross Margin % ? | 75.2% | 15% | 100.0 ptsExceptional (75.2%) - Strong pricing power |
| Drawdown from 52-Wk High ? | 5.4% | 15% | 20.0 ptsBarely a Dip (5.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVCR
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
- Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
- The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.